Table 3 Chemotherapy, antiemetic prophylaxis and CINV outcomes

N

3,606

1,742

186

4,497

2,691

1,806

1,154

764

390

CT tx days, mean (SD)

4.2 (1.2)

4.3 (1.3)

4.2 (1.2)

0.0297

6.1 (3.7)

6.2 (3.6)

6.1 (3.6)

NS

5.8 (4.3)

6.3 (4.7)

4.9 (3.2)

<0.0001

All antiemetic claims

9.1 (5.1)

9.9 (5.5)

8.3 (4.6)

<0.0001

10.2 (6.7)

11.4 (7.2)

8.5 (5.4)

<0.0001

13.0 (8.0)

15.3 (8.0)

8.5 (5.6)

<0.0001

All 5-HT₃ RA claims

7.0 (3.9)

7.9 (4.2)

6.2 (3.4)

<0.0001

9.2 (6.0)

10.3 (6.4)

7.7 (4.9)

<0.0001

10.9 (6.9)

13.1 (6.8)

6.4 (4.4)

<0.0001

Days with hospital/ED associated CINV events

0.1 (0.7)

0.1 (0.9)

0.1 (0.4)

0.0052

0.3 (1.3)

0.3 (1.4)

0.2 (1.2)

0.0004

0.6 (2.0)

0.7 (2.1)

0.6 (1.9)

0.0499

Pts with > =1 hospital/ED associated CINV events, N (%)

161 (4.5)

95 (5.5)

66 (3.5)

0.0055

516 (11.5)

345 (12.8)

171 (9.5)

0.0005

230 (19.9)

166 (21.7)

64 (16.4)

0.0324